Nanyang Biologics, a Singapore-based biotech company, has announced a groundbreaking partnership with technology leaders NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to advance AI-driven drug discovery. The collaboration, formalised through a Memorandum of Understanding (MOU) signed at the AI4Life Summit on 26 August 2025, aims to create the world’s largest natural drug compound library in Singapore over the next 12 months.
The initiative, supported by the Singapore government, seeks to position the city-state as a global hub for AI-driven healthcare and biomedical innovation. The AI4Life Summit, held at the Fullerton Hotel, featured keynote presentations from the involved parties and a panel discussion on strategic infrastructure for therapeutic innovation. The event was graced by Goh Hanyan, co-chair of the Committee on Technology and Innovation, who highlighted the significance of the collaboration in strengthening Singapore’s role in global healthcare innovation.
Nanyang Biologics’ Chairman, Roland Ong, emphasised the transformative potential of the partnership, stating, “We are working together to transform nature’s pharmacy into tomorrow’s solutions for health and well-being.” The company’s proprietary AI platform, Vecura, will be pivotal in accelerating drug discovery from natural sources, building on research conducted by the NYB–NTU Joint Laboratory since 2019.
This collaboration not only aims to expedite the drug discovery process but also to foster a multidisciplinary workforce in Singapore, bridging AI, biology, and drug development. The initiative is expected to enhance Singapore’s competitiveness and contribute to the global healthcare landscape by leveraging AI to address unmet medical needs.
“`
